Introduction {#S1}
============

Subjective tinnitus, defined as the perception of a sound when no external stimulation is present, is a condition that affects a large portion of the world population, with over 16 million subjects in the US reporting frequent tinnitus [@R01]. Tinnitus has been widely studied in humans and animals to better understand the molecular mechanisms that underlie its onset and persistence, and to identify drugs that could be used for treatment.

Short-term tinnitus has been reported following administration of high-doses of sodium salicylate. The molecular mechanisms through which salicylate induces tinnitus have been explored [@R02], especially its effects on the cyclooxygenase which blocks the conversion of arachidonic acid to prostaglandin H2 [@R03] [@R04]. The increased concentration of arachidonic acid acts on N-methyl-D-aspartic acid (NMDA) receptors, inducing both peripheral and central effects. NMDA receptors are expressed on the synapses between inner hair cells and cochlear spiral ganglion neurons [@R05]. In vitro, salicylate potentiates the NMDA class of glutamatergic currents on cochlear spiral ganglion neurons. Salicylate also impairs outer hair cell (OHC) electromotility [@R06], although prolonged treatment has been reported to strengthen OHC motility [@R07] [@R08] and reduces blood flow in the cochlea [@R09]. High doses of salicylate increase the threshold and reduce the amplitude of the compound action potential (CAP), but salicylate paradoxically results in hyperactivity in the central auditory cortex [@R10].

Memantine, a drug recently approved for the treatment of moderate to severe Alzheimer\'s disease [@R11], has been reported to suppress excitatory neurotransmission between the hair cell and auditory nerve afferent fibers by blocking NMDA receptors [@R12], and is likely to exert effects on the central auditory pathways [@R13]. Memantine has been previously studied for its ability to suppress tinnitus in animals [@R14] and humans [@R15] and found to have little or no effect; however, Zheng et al., in 2012 [@R16], reported encouraging effects of memantine in noise-induced tinnitus in the rat.

The animal model used to study tinnitus is the gap prepulse inhibition of the startle reflex (GPIAS); the method was developed by Turner in 2006 [@R17] and later adopted and optimized by others [@R18]^-^[@R23]. Since GPIAS does not require any training and relies on a reflex response, it is a very efficient method of testing for tinnitus compared to time consuming operant conditioning techniques, thereby allowing a larger number of animals to be evaluated [@R24].

The primary goal of this study was to determine if memantine, a NMDA antagonist, would affect salicylateinduced tinnitus. A secondary goal was to determine what effects memantine or the combination of memantine and salicylate would have on DPOAE and ABR.

Materials and methods {#S2}
=====================

Animals {#S2a}
-------

Thirty-six adult male Sprague Dawley rats (3-5 months, 220-450 g) were used for this study. Rats were divided into three groups: a SAL group (n = 12) injected IP with salicylate (300 mg/kg/d) in bacteriostatic saline, 50 mg/ ml (Sigma); a MEM group (n = 12) treated with memantine at a dose of 5 mg/kg/d diluted in bacteriostatic saline, 50 mg/ml (Sigma); a SAL+MEM group (n = 12) injected with salicylate and memantine combined at the dosage used in the other groups. All animals were treated daily for four consecutive days; drug administration was performed 2 h before testing for tinnitus.

The experimental protocol was approved by the Institutional Animal Care and Use Committee of the Catholic University of the Sacred Heart, Rome Italy. Animals were housed in a colony with a 12 h light-dark cycle; food and water were available ad libitum.

Gap prepulse inhibition of acoustic startle {#S2b}
-------------------------------------------

Tinnitus was assessed using gap prepulse inhibition of acoustic startle as described in our previous investigation [@R24]. Rats were placed in an acoustically transparent wire mesh cage (7.2 cm W, 20 cm L, 6.5 cm H) on a Plexiglas platform; the platform (20 cm × 10 cm) rested on a 50 mm piezoelectric transducer (MCM 28-745). The test apparatus was located in a soundproof chamber equipped with a tweeter (Fostex FT17H) on the chamber\'s ceiling about 15 cm above the rat\'s head. The continuous background noise, gap stimulus, prepulse noise burst and startle stimulus were generated with a digital-to-analogue converter at \~100 kHz sampling rate (Tucker Davis Technologies, RP2.1, PA5, SA1). Startle amplitude measured by the piezoelectric transducer was amplified (10-100×), low-pass filtered at 1,000 Hz; WPI, USA) and fed to the analogue-to-digital converter on a separate data acquisition module (TDT, RP2.1) using custom software.

GPIAS sessions were composed of 80 silent gaps trials (gap) embedded in narrow band noise and 80 no-gap trials (no-gap) in the narrow band noise ([Fig. 1A-C](#F1){ref-type="fig"}). Twenty gap and 20 no-gap trials were made at each of the four narrow band noises centred at 6, 12, 16 or 20 kHz. Gap and no-gap trials were presented in pairs in random order. Trials were separated by a variable period ranging from 7 to 15 sec long. Animals were given a 2-min acclimation period at the beginning of each session during which no gaps or startle sounds occurred. Gap trials were composed of a 60 dB SPL continuous narrow band noise (1,000 Hz wide, centered at 6, 12, 16 and 20 kHz), and a 50 msec startle stimulus (broadband noise burst, 116 dB SPL, 50 msec length, 5 msec rise/fall time) preceded by a 100 msec silent gap that ended 100 msec before the onset of the startle stimulus. In no-gap trials, the background sound was continuous without a silent period preceding the startle stimulus. The amplitude of the startle reflex signal was measured as the root-mean-square (RMS) voltage on gap and no-gap trials. Noise burst prepulse inhibition of the acoustic startle reflex (NBPIAS) was used to determine the audibility of the narrow band noises used for GPIAS assessment ([Fig. 1DE](#F1){ref-type="fig"}). NBPIAS was recorded using the same equipment as GPIAS except that the background noise was removed and the startle stimulus was presented alone (i.e. in quiet) or was preceded by a 60 dB SPL narrow band noise burst (1,000 Hz wide, 100 msec, 5 msec rise/fall time, centred at 6, 12, 16 or 20 kHz.). Twenty noise burst and 20 quiet trials were made at each tested frequency.

![Schematics of the animal model used to highlight the presence and time course of tinnitus in rats. Gap prepulse inhibition of acoustic startle: (A) Following the startle stimulus without a prepulse gap results in a large amplitude startle reflex. (B) When a 50 msec gap prepulse is inserted prior to the startle stimulus, the startle reflex response is significantly reduced. (C) Tinnitus fills in the gap and the animal can no longer hear the silent gap, resulting in a reduction of the startle response similar to the no-gap condition. (D) Noise burst prepulse inhibition of acoustic startle: NBPIAS is used to evaluate whether the animal can hear the background noise used in the GPIAS paradigm. In NBPIAS, the startle stimulus is presented in a silent environment; this results in a large startle response. (E) When a 60 dB noise burst prepulse precedes the startle stimulus, the startle response is reduced.](0392-100X-34-198-g001){#F1}

Gap and noise burst prepulse inhibition of acoustic startle were calculated as a percentage for each frequency using the formulas 1-(gap/no-gap) for GPIAS and 1- (noise burst/quiet) for NBPIAS. For each frequency, a significant reduction of GPIAS was interpreted as behavioural evidence of tinnitus. Conversely, significant inhibition of the startle response in NBPIAS sessions was interpreted as evidence that the animal could hear the narrow band noise used in GPIAS sessions.

Animals were tested daily with GPIAS and NBPIAS before and 2 h after each drug administration; measurements were obtained for five consecutive days (four measurements during treatment; one post treatment).

Auditory brainstem response recordings {#S2c}
--------------------------------------

Hearing function was evaluated in all animals using the auditory brainstem response (ABR). ABR thresholds were obtained at 6, 12, 16, 24 and 32 kHz in all animals before and 14 days after the end of the drug treatment. Rats were anaesthetized (ketamine 10 mg/kg) and placed in a sound attenuating booth; the non-inverting (+) electrode was inserted at the vertex, the inverting (-) electrode was placed near the pinna of the test ear and the ground electrode was placed near the pinna of the opposite ear. A TDT System 3 (BioSigRP, Tucker--Davis Technologies, Alachua, Florida, USA) data acquisition system was used for stimulus generation and data acquisition. Tone bursts corresponding to tested frequencies were presented monaurally in an open field (Fostex, TD28D, USA) with the speaker pointed towards the test ear at a distance of 1 cm; the contralateral ear was plugged with a silicon plug. Responses were filtered (100-3,000 Hz band pass), digitized (10 kHz sampling rate) and averaged over 1,000 samples at each frequency. Threshold testing began with the stimulus presented at 100 dB SPL in order to generate a clear ABR waveform; then the intensity was reduced in 10 dB steps until the ABR response disappeared. Next, the intensity of the stimulus was increased in 5 dB steps from below threshold until the ABR response reappeared. The ABR threshold was defined as the lowest intensity at which the ABR could be detected and replicated [@R25] [@R26].

Distortion product otoacoustic emissions {#S2d}
----------------------------------------

DPOAEs were measured unilaterally using an otoacoustic emission system (Intelligent Hearing System, Miami, FL, USA). The f2/f1 ratio of the primary tones was set to 1.2. DPOAE input/output functions were measured at f2 frequencies of 4, 8, 12, 16 and 20 kHz. The f1 intensity, L1, always presented +10 dB above the f2 intensity, L2. Animals were anaesthetized with ketamine as described above and placed on a heating pad in a sound-attenuating booth. The probe assembly was placed in the animal\'s external ear canal. Input/output functions were obtained by increasing L1 intensity from 25 to 70 dB SPL at f2 frequencies of 4, 8, 12, 16 and 20 kHz (32 sweeps per frequency pair). DPOAEs were recorded before and 2 h after each drug treatment for 5 consecutive days.

Statistical analysis {#S2e}
--------------------

GPIAS and NBPIAS data were analyzed using a two-way repeated measures analysis of variance (RM-ANOVA, α \< 0.05); post-hoc testing was performed using Tukey\'s test for multiple comparisons. Significant differences between frequency-specific data recorded at each time point and baseline values were analyzed using a one-way ANOVA (p \< 0.05). Statistical analysis of ABR and DPOAE measurements were performed using a one-way ANOVA with post-hoc Student-Newman-Keuls analysis. All results were presented as mean ± SEM.

Results {#S3}
=======

Tinnitus assessment {#S3a}
-------------------

[Figure 1A-C](#F1){ref-type="fig"} is a schematic of the GPIAS paradigm that shows the stimulus conditions and hypothetical results for no-gap, gap and tinnitus conditions. [Figure 2](#F2){ref-type="fig"} shows the percent GPIAS values at 6, 12, 16 and 20 kHz before and at various time points during the four days of drug treatment. Baseline GPIAS values are represented by the horizontal dotted line (line width equals baseline standard deviation; baseline values were 43.8, 42.3, 37.6 and 38.8% for 6, 12, 16 and 20 kHz respectively.

![Data obtained in our animal groups showing the time course of tinnitus for different treatments. Percent GPIAS in rats treated with salicylate alone or salicylate and memantine plotted by frequency; NBPIAS data are also shown for comparison. The horizontal dotted line represents baseline data. Rats treated with memantine alone showed no evidence of tinnitus (data not shown). Rats treated with salicylate alone showed transient tinnitus-like behaviour with a pitch near 16 kHz, starting 2 hours after the first injection, lasting for the entire length of treatment (4 days) and resolving spontaneously 24 hours after the last day of drug administration (24 h POST). In rats treated with salicylate and memantine, tinnitus-like behaviour was greatly attenuated, particularly during the first 48 hours of treatment, suggesting that memantine must suppress tinnitus-like behaviour at peripheral or central NMDA receptors.](0392-100X-34-198-g002){#F2}

Rats treated with salicylate alone (SAL) showed a significant reduction in GPIAS at 16 kHz, consistent with tinnituslike behaviour with a pitch near 16 kHz. A significant reduction occurred between 2 and 72 h with a peak at 48 hours; GPIAS returned near to baseline levels 24 h after the last day of drug administration. A statistically significant decrease in mean GPIAS was observed at 16 kHz at 2 h (p = 0.041), 24 h (p = 0.036), 48 h (p = 0.019) and 72 h (p = 0.047) during treatments; 24 h after the end of the treatment mean values returned near to baseline levels (34.95%; p = 0.65). GPIAS values did not show a significant change at 6, 12 and 20 kHz during the salicylate treatment (2 to 72 h).

Rats treated with memantine alone (MEM) showed no significant changes in GPIAS compared to baseline values during the entire length of treatment (data not shown). Rats treated with a combination of salicylate and memantine (SAL+MEM) showed less reduction in GPIAS than rats treated with salicylate alone (SAL), particularly at 16 kHz during the first 48 hours of treatment. There was a statistically significant difference at 48 h between the SAL and the SAL+MEM groups (p = 0.023).

NBPIAS was also tested in the SAL, SAL+MEM and MEM groups; no significant changes were observed over the entire testing period between baseline measures and values obtained during treatments and post-treatment. Data for all groups are compared in [Figure 2](#F2){ref-type="fig"}.

ABR {#S3b}
---

Baseline ABR threshold values recorded before treatment did not show a statistically significant group difference among the SAL, MEM and SAL+MEM groups (Two-way ANOVA, p = 0.36). No significant difference was seen between baseline and posttreatment thresholds measured 14 days after the end of treatment (p = 0.41). These results indicate that salicylate, memantine or the combination of the two does not produce any long term change in hearing thresholds.

DPOAEs {#S3c}
------

DPOAEs were tested in all animals at 4, 8, 12, 16 and 20 kHz, and were measured before, during (2, 24, 48 and 72 h) and 24 h after SAL, MEM and SAL+MEM treatments. A progressive decrease in amplitude was observed in the salicylate group for low-level DPOAEs at 8, 12 and 16 kHz. High-level DPOAEs were slightly affected; the largest changes occurred 2 h after salicylate injection at 8 and 12 kHz. Amplitudes returned to near baseline values within one day post-treatment. Memantine alone had no effect on DPOAE amplitude. Treatment with SAL+MEM resulted in a decline of DPOAE amplitude comparable to salicylate alone. Data for all groups (SAL, MEM, SAL+MEM) are plotted in [Figures 3A and 3B](#F3){ref-type="fig"}.

###### 

The effect of salicylate and memantine on outer hair cells. DPOAE measurements in animals treated with memantine, salicylate or a combination of both. Data from baseline and 2, 24 and 48 h time points are shown in Fig 3A; data from baseline and 72, 24 h post time points are shown in Fig 3B. Memantine alone had no effect on DPOAE amplitude whereas salicylate alone caused a progressive decrease in DPOAE over the 4-day treatment. The combination of both drugs resulted in DPOAE amplitudes similar to those obtained in animals treated with salicylate alone.

![](0392-100X-34-198-g003a)
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Discussion {#S4}
==========

The effect of memantine on salicylate-induced tinnitus {#S4a}
------------------------------------------------------

Memantine, a non-competitive NMDA antagonist that affects neurotransmission between inner hair cells and afferent auditory nerve fibers, has been hypothesized to suppress tinnitus. Memantine is currently approved for the treatment of moderate to severe cases of Alzheimer\'s disease, and has been proposed for the treatment of Parkinson\'s disease and certain forms of dementia [@R11]. Given its availability in clinical settings, memantine and its analogues have been considered as potential treatments for tinnitus [@R27]. To test this hypothesis, Lobarinas and colleagues treated rats with a moderate dose (150 mg/kg) of salicylate and obtained behavioural evidence of tinnitus using an operant lick suppression technique [@R14]. Rats were then treated with 1.5 or 3 mg/kg of memantine combined with 150 mg/kg of salicylate to determine if memantine would suppress tinnitus-like behaviour. While tinnitus was not completely suppressed by 1.5 or 3 mg/kg memantine, the molecule tended to reduce the tinnitus-like behaviour, which was more pronounced at the higher dose. Therefore, while tinnitus was not completely abolished by memantine, the evidence suggested that tinnitus severity might be somewhat reduced. Lobarinas attempted to use a higher dose of memantine, but found that 10 mg/ kg disrupted the operant behaviour; consequently, higher doses of memantine were not evaluated for suppression of tinnitus.

Figueredo et al. published a randomized, double-blind placebo-controlled trial in which tinnitus was studied in 60 patients, and its severity was monitored using the Tinnitus Handicap Inventory (THI). In this study, memantine was administered at a dose of 20 mg per day for 90 days. They reported no statistically significant differences between patients in the memantine group and those in the placebo group [@R15]. Taken together, these two studies suggest that memantine may have little or no effect on tinnitus.

In the current study, using GPIAS as our behavioural metric for tinnitus, we observed evidence of tinnitus at 16 kHz with 300 mg/kg of salicylate and found that the 5 mg/kg dose of memantine significantly reversed tinnitus- like GPIAS behaviour. Thus, our results suggest that a 5 mg/kg dose of memantine, nearly twice that used by Lobarinas, can suppress tinnitus. Importantly, animals treated with memantine alone did not show significant changes in GPIAS.

A recent paper from Zheng et al. 16 investigated the efficacy of a 5 mg/kg dose of memantine in rats with behavioural evidence of tinnitus assessed with an operant lick-suppression technique. They found that a 1 h, 110 dB, 16 kHz traumatizing tone induced tinnitus having a pitch of 32 kHz in five of eight exposed rats. After treatment with 5 mg/kg memantine, only 2 of the 5 rats continued to show evidence of noise-induced tinnitus, i.e., memantine eliminated signs of tinnitus in 3 of 5 rats.

Our results are consistent with those of Zheng suggesting that higher doses of memantine may suppress tinnitus. However, it should be noted that while the 5 mg/kg dose of memantine caused a statistically significant improvement in tinnitus, our GPIAS values during SAL+MEM were still slightly below their baseline GPIAS values. In other words, while 5 mg/kg memantine significantly improved tinnitus-like behaviour, it may not have completely suppressed tinnitus. Likewise, memantine only led to a reduction in noise-induced tinnitus in 60% of subjects in the Zheng study. It is conceivable that higher doses of memantine may be more effective in suppressing tinnitus; however, the behavioural side effects, as noted by Lobarinas [@R28] may outweigh the benefits.

Salicylate, memantine and auditory function {#S4b}
-------------------------------------------

Our results show that memantine had no effect on DPOAE amplitudes during treatment. These results are consistent with the view that memantine acts on neuronal NMDA receptors, which are not expressed in adult OHC [@R29]. In addition, our results show that memantine had no effect on OHC function, as reflected in DPOAE, when administered with salicylate; results are consistent with the view that memantine is not acting on the OHC. Short-term treatment with salicylate, memantine or the combination of the two had no permanent effects on ABR; thresholds recorded 14 days after drug treatments showed no differences compared to baseline. Serial DPOAE measurements from 2 to 72 h of salicylate treatment revealed a cumulative dose-dependent effect mainly on low-level DPOAEs at 8, 12 and 16 kHz; i.e. DPOAE amplitudes tended to decrease over the 3 day treatment. These results are consistent with previous results showing a gradual decline in DPOAE amplitude over several days of salicylate treatment [@R30]. However, DPOAE amplitudes recovered to within normal limits within 1 day after the end of treatment. Since animals treated with salicylate and memantine showed DPOAE alteration comparable to salicylate alone, the effects of memantine on GPIAS are unlikely to be due to changes in OHC function.

Conclusions {#S5}
===========

The present study confirms that salicylate can induce transient, reversible tinnitus when administered at high doses. More importantly, our behavioural assessment of tinnitus using GPIAS suggests that a 5 mg/kg dose of memantine, which was nearly two fold greater than that used by Lobarinas, can significantly reduce tinnitus-like behaviour. Since higher doses (10 mg/kg) of memantine can disrupt behaviour, effective treatment of tinnitus using NMDA antagonists may require careful titration of the dose to obtain clinical efficacy without inducing deleterious side effects. The suppression of tinnitus-like behaviour in our study was achieved with systemic memantine treatment, it is therefore unclear if the therapeutic effect of memantine is occurring at the IHC-auditory nerve fibre synapse, as proposed by Puel et al. [@R05], or if it is occurring at multiple sites within the central auditory pathway. Given the encouraging results and clinical availability of memantine, it would be interesting to further explore its efficacy in humans with tinnitus. Since the effective therapeutic window for drug dosing appears to be relatively narrow, effective tinnitus therapy may require careful escalation of the dose of memantine to achieve optimal therapy with minimal side effects.
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